Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis

This study has been completed.
MedImmune Ltd
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: November 29, 2011
Last updated: January 12, 2015
Last verified: April 2014
The study is designed to evaluate the clinical efficacy and safety of tralokinumab as compared to placebo. Investigational product will be administered as subcutaneous injection. All patients will continue background therapy for ulcerative colitis as per local standards of care in addition to investigational product.

Condition Intervention Phase
Ulcerative Colitis
Drug: tralokinumab
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIa, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study to Evaluate the Efficacy and Safety of Tralokinumab (CAT-354), a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), as add-on Therapy, on Clinical Response in Patients With Active, Moderate-to-severe, Ulcerative Colitis

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Clinical response (defined as a decrease in Mayo score from baseline of at least 3 points and at least 30% with an accompanying decrease in the sub score for rectal bleeding of at least 1 point or absolute sub score for rectal bleeding of 0 or 1). [ Time Frame: At week 8. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Mayo score (calculated as the sum of the four sub-scores: stool frequency rectal bleeding, endoscopy findings and the physician's overall assessment of the same in addition to abdominal discomfort and patient's general sense of well-being). [ Time Frame: From baseline to week 8. ] [ Designated as safety issue: No ]
  • Mucosal healing (defined as an improvement of the endoscopy sub-score (from the Mayo score) at week 8 from 3 or 2 to ≤1 point, or from 1 to 0 points). [ Time Frame: At week 8. ] [ Designated as safety issue: No ]
  • Change in partial Mayo score (calculated as the sum of the scoring from the three sub-score areas: stool frequency, rectal bleeding and the physician's global assessment). [ Time Frame: From baseline to week 4, 8, 12, 16, 20, and 24. ] [ Designated as safety issue: No ]
  • Clinical remission (defined as Mayo score of 2 or lower with no individual sub-score exceeding 1 point). [ Time Frame: After 8 weeks. ] [ Designated as safety issue: No ]
  • Histologic disease activity (assessment based on the modified Riley score). [ Time Frame: At baseline and week 8. ] [ Designated as safety issue: No ]
  • Markers of disease activity (CRP, calprotectin) and intestinal leakiness (albumin). [ Time Frame: At baseline, week 4, 8, 12, 16, 20, and 24. ] [ Designated as safety issue: No ]
  • Immunogenicity: incidence of anti-drug antibodies (ADA) to tralokinumab in serum. [ Time Frame: Pre-dose sampling at baseline, week 8, 12, 16, and 24. ] [ Designated as safety issue: No ]
  • Tralokinumab serum concentration. [ Time Frame: Pre-dose sampling at baseline, week 4, 8, 12, 16, 20, and 24. ] [ Designated as safety issue: No ]
  • Safety and tolerability of tralokinumab in terms of adverse events, safety laboratory values, electrocardiograms, vital signs, weight, and physical examination findings. [ Time Frame: From baseline to week 24 ] [ Designated as safety issue: Yes ]

Enrollment: 147
Study Start Date: March 2012
Study Completion Date: June 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
tralokinumab (CAT-354) sc injection
Drug: tralokinumab
2 sc injections of every 2 weeks for 12 weeks.
Placebo Comparator: 2
placebo sc injection
Drug: placebo
2 sc injections of every 2 weeks for 12 weeks.

Detailed Description:
A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed ulcerative colitis at least 90 days prior randomisation.
  • Men or women age 18 - 75 years.
  • Non-hospitalized patients with moderate-severe ulcerative colitis treated with stable background UC therapy (e.g. containing 5-aminosalicylates, and/or low dose of glucocorticosteroids, and/or purine analogue) prior to randomization.
  • Females of childbearing potential who are sexually active with a nonsterilized male partner must use highly effective contraception from Day1.
  • Nonsterilized males or sterilized males who are ≤1 year post-vasectomy who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception.

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • History of colostomy.
  • Current diagnosis of indeterminate colitis, Crohn's disease, ischemic colitis, fulminant colitis and/or toxic megacolon and patients with ulcerative colitis limited to the rectum (ulcerative proctitis).
  • Hepatitis B, C or HIV.
  • History of cancer.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01482884

Czech Republic
Research Site
Ceske Budejovice, Czech Republic
Research Site
Hradec Kralove, Czech Republic
Research Site
Olomouc, Czech Republic
Research Site
Praha 1, Czech Republic
Research Site
Praha 5, Czech Republic
Research Site
Praha 7, Czech Republic
Research Site
Amiens Cedex 1, France
Research Site
Caen, France
Research Site
Clichy, France
Research Site
Nice Cedex 3, France
Research Site
Pessac, France
Research Site
Rouen, France
Research Site
Vandoeuvre Les Nancy, France
Research Site
Ludwigshafen, Germany
Research Site
Oelde, Germany
Research Site
Potsdam, Germany
Research Site
Wangen, Germany
Research Site
Firenze, Italy
Research Site
Padova, Italy
Research Site
Roma, Italy
Research Site
Rozzano, Italy
Research Site
Bydgoszcz, Poland
Research Site
Częstochowa, Poland
Research Site
Sopot, Poland
Research Site
Warszawa, Poland
Research Site
Łódź, Poland
United Kingdom
Research Site
Cambridge, United Kingdom
Research Site
Coventry, United Kingdom
Research Site
Oxford, United Kingdom
Research Site
Shrewsbury, United Kingdom
Sponsors and Collaborators
MedImmune Ltd
Study Director: Mark Berner Hansen, MD, PhD AstraZeneca R&D Mölndal Pepparedsleden 1, S-431 83 Mölndal, Sweden
Principal Investigator: Silvio Danese, MD, PhD IBD Center, Instituto Clinico Humanitas, Department of Gastroenterology, Via Manzoni 56, 20089 Rozzano, Milan, Italy
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01482884     History of Changes
Other Study ID Numbers: D2211C00001, EudraCT number 2011-004812-40
Study First Received: November 29, 2011
Last Updated: January 12, 2015
Health Authority: Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Paul-Ehrlich-Institut
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by AstraZeneca:
inflammatory bowel disease
moderate to severe ulcerative colitis

Additional relevant MeSH terms:
Colitis, Ulcerative
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on December 01, 2015